SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Apricus Biosciences
An SI Board Since September 2014
Posts SubjectMarks Bans Symbol
2026 18 0 APRI
Emcee:  mokelumne river Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
301great points James, and I agree , the new management has a totally different viseico20-11/11/2014
300The new presentation is really a strategy laying out steps to be taken to get Fimokelumne river-11/11/2014
299Looking on the bright side...our market cap has improved with all those extra shphoenix_rising-11/11/2014
298That is their best presentation yet. Happy to see Femprox back on it along withphoenix_rising-11/11/2014
297a good article on testosterone and ED Testosterone first? Before Viagra appeico20-11/11/2014
296here's an interesting trial on Fispemifene for ED, no results posted though eico20-11/11/2014
295new corporate presentation cdn.irdirect.neteico20-11/11/2014
294I agree SL,. new things hereeico20-11/10/2014
293Thanks James for the follow up to your post. I find it humorous that there are Strong Long-11/10/2014
292Eman, I feel better that Pascoe reaffirmed the importance of the Androxal approvmokelumne river-11/10/2014
291Good points James, what i liked were Pascoe's comments on the regulatory staeico20111/10/2014
290Making my way through the transcript, seeing if loose ends can be tied up: Secomokelumne river-11/10/2014
289good point MI, good to know the cost on Vitaros to manufacture the small royalteico20-11/10/2014
288Actually, if you are referring to a next quarterly report. It would be the 10K Mirror Image-11/10/2014
287yes, we will have to wait another 3 month to see some revenue.....Hellsails-11/10/2014
286this .4 M is a wash, it goes back to the manufacturer Therapexeico20-11/10/2014
285correction, the .4M is for manufacturing rev in Q3, on 179k doses, not royalty reico20-11/10/2014
284good point HS, not bad for a 2 week start, add growth to that as welleico20-11/10/2014
283written like this , it sounds that things are doing quite well... see if that rHellsails-11/10/2014
282EU alprosatdil sales were 100M in 2012 Pascoe said previously, no specific numbeeico20-11/10/2014
281"and $0.4 million for the initial revenues from the sale of Vitaros" Hellsails-11/10/2014
280Regarding the question of reimbursement , in Sweden Vitaros is not reimbursed . Hellsails-11/10/2014
279I hope so too Eico ( that they share some specific data on units shipped, formulMirror Image-11/10/2014
278excellent info MI, thanks, If the injectable is in shortage then Vitaros is the eico20111/9/2014
277Very Interesting Erectile Dysfunction Presentation - Information pertinent to thMirror Image-11/8/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News